Samy Suissa PhD, FRSC, FCAHS
Distinguished James McGill Professor of Epidemiology, Biostatistics and Medicine, McGill University; Director, Centre for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montreal, Quebec, CanadaProfessor Suissa is a Distinguished James McGill Professor of Epidemiology and Biostatistics at McGill University, and Director of the Centre for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Canada. He heads the Canadian Network for Observational Drug Effect Studies (CNODES).
Professor Suissa has conducted extensive research on the real-world effects of medications for different chronic diseases, including asthma, COPD and IPF. He specializes in research methods and authored over 550 peer-reviewed papers.
He serves on the editorial boards of various scientific journals. He is a fellow of the Royal Society of Canada and of the Canadian Academy of Health Science, received the Distinguished Investigator award from the Canadian Institutes of Health Research and the FC Donders Professorship award from Universiteit Utrecht, Netherlands.
Disclosures
S Suissa has attended scientific advisory committee meetings or consulted for AstraZeneca, Atara, Boehringer-Ingelheim, Merck, Novartis, Panalgo, Pfizer and Seqirus, and received speaking fees from AstraZeneca, Boehringer-Ingelheim and Novartis.
Recent Contributions to PracticeUpdate:
- Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-Line Drugs
- Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
- Association Between Use of Inhaled Corticosteroids and the Risk of All-Cause Mortality in Patients With COPD
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes